BİYOERİYEBİLEN STENTLER

Mehmet Bülent Vatan; Mustafa Tarık Ağaç; Ersan Tatlı; Muhammed Necati Murat Aksoy

BİYOERİYEBİLEN STENTLER

Yıl 2017, Cilt: 3 Sayı: 2, 92 - 97, 22.06.2017

Mehmet Bülent Vatan Mustafa Tarık Ağaç Ersan Tatlı Muhammed Necati Murat Aksoy

https://izlik.org/JA52AG93YS

Öz

Perkütan koroner girişim yöntemleri
son dekadda oldukça hızlı bir gelişim göstermiştir. Bu gelişimin en son aşaması
ise biyoeriyebilen stent teknolojisidir. Biyoeriyebilen stentlerin metalik
yabancı iskeleti olmaması nedeniyle vasküler inflamasyon, restenoz, stent
trombozu ve neoaterosklerozu azaltma gibi potensiyel avantajları olabileceği
düşünülse de yapılan prospektif çalışmaların orta dönem sonuçları büyük hayal
kırıklığı yaratmıştır. Günümüzde bu teknolojinin klinik kullanıma yaygın olarak
sunulması için geliştirme faaliyetleri sürmektedir. Bu derlemede biyoeriyebilen
stent teknolojisi ile ilgili pre-klinik ve klinik değerlendirmelere yer
verilmiştir.

Anahtar Kelimeler

Biyoeriyebilen iskelet , perkütan koroner girişim

Kaynakça

. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet (London, England). 1978;1(8058):263
2. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronaryartery stenosis: Percutaneous transluminal coronary angioplasty. The New England Journal of Medicine. 1979;301(2):61–8
3. Sigwart U, Urban P, Golf S, Kaufmann U, Imbert C, Fischer A, Kappenberger L. Emergency stenting for acute occlusion after coronary balloon angioplasty. Circulation. 1988;78(5 Pt 1):1121–27.
4. Roubin GS, Cannon AD, Agrawal SK, Macander PJ, Dean LS, Baxley WA, Breland J. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation. 1992;85(3):916–27
5. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, , Emanuelsson H, Marco J, Legrand V, Materne P, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. The New England Journal of Medicine. 1994;331(8):489–95
6. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. The New England Journal of Medicine. 1994;331(8):496–501
7. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. The New England Journal of Medicine. 2004;350(3):221–31
8. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. The New England Journal of Medicine. 2002;346(23):1773–80
9. Tenekecioglu E, Farooq V, Bourantas CV, Silva RC, Onuma Y, Yılmaz M, Serruys PW. Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention. BMC Cardiovascular Disorders. 2016;16:38.
10. Iqbal J, Onuma Y, Ormiston J, Abizaid A, Waksman R, Serruys P. Bioresorbable scaffolds: Rationale, current status, challenges, and future. European Heart Journal. 2014;35(12):765–76.
11. Zhang Y, Bourantas CV, Farooq V, Muramatsu T, Diletti R, Onuma Y, et al. Bioresorbable scaffolds in the treatment of coronary artery disease. Medical Devices (Auckland, NZ). 2013;6:37–48
12. Onuma Y, Serruys PW. Bioresorbable scaffold: The advent of a new era in percutaneous coronary and peripheral revascularization? Circulation. 2011;123(7):779–97.
13. Verheye S, Ormiston JA, Stewart J, Webster M, Sanidas E, Costa R, et al. A next-generation bioresorbable coronary scaffold system: From bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. JACC Cardiovascular Interventions. 2014;7(1):89–99
14. Nikolsky E, Mehran R, Dangas G, Fahy M, Na Y, Pocock SJ, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. European Heart Journal. 2007;28(16):1936–45
15. Kitabata H, Waksman R, Warnack B. Bioresorbable metal scaffold for cardiovascular application: current knowledge and future perspectives. Cardiovasc Revasc Med 2014;15:109-16
16. Diletti R, Serruys PW, Farooq V, et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J 2012;164:654-63
17. Kereiakes DJ, Ellis SG, Popma JJ, et al. Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: design of and rationale for the ABSORB III randomized trial. Am Heart J 2015;170:641-51
18. Biscaglia S, Ugo F, Ielasi A, et al. Bioresorbable Scaffold vs. Second Generation Drug Eluting Stent in Long Coronary Lesions requiring Overlap: A Propensity-Matched Comparison (the UNDERDOGS study). Int J Cardiol 2016;208:40-5
19. Sabaté M, Windecker S, Iñiguez A, et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J. 2016;37(3):229-40
20. Kimura T, Kozuma K, Tanabe K, et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015;36(47):3332-42
21. Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3-year, randomized, controlled, single-blind, multicenter trial. Lancet. 2016; Epub ahead of print.
22. Ellis SG, Kereiakes DJ, Metzger C, et al., on behalf of the ABSORB III Investigators. The 2-year Clinical Outcomes of the ABSORB III Trial:. Presented by Dr. Stephen Ellis at the American College of Cardiology Annual Scientific Session (ACC 2017), Washington, DC, March 18, 2017

Yıl 2017, Cilt: 3 Sayı: 2, 92 - 97, 22.06.2017

Mehmet Bülent Vatan Mustafa Tarık Ağaç Ersan Tatlı Muhammed Necati Murat Aksoy

https://izlik.org/JA52AG93YS

Öz

Kaynakça

. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet (London, England). 1978;1(8058):263
2. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronaryartery stenosis: Percutaneous transluminal coronary angioplasty. The New England Journal of Medicine. 1979;301(2):61–8
3. Sigwart U, Urban P, Golf S, Kaufmann U, Imbert C, Fischer A, Kappenberger L. Emergency stenting for acute occlusion after coronary balloon angioplasty. Circulation. 1988;78(5 Pt 1):1121–27.
4. Roubin GS, Cannon AD, Agrawal SK, Macander PJ, Dean LS, Baxley WA, Breland J. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation. 1992;85(3):916–27
5. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, , Emanuelsson H, Marco J, Legrand V, Materne P, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. The New England Journal of Medicine. 1994;331(8):489–95
6. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. The New England Journal of Medicine. 1994;331(8):496–501
7. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. The New England Journal of Medicine. 2004;350(3):221–31
8. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. The New England Journal of Medicine. 2002;346(23):1773–80
9. Tenekecioglu E, Farooq V, Bourantas CV, Silva RC, Onuma Y, Yılmaz M, Serruys PW. Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention. BMC Cardiovascular Disorders. 2016;16:38.
10. Iqbal J, Onuma Y, Ormiston J, Abizaid A, Waksman R, Serruys P. Bioresorbable scaffolds: Rationale, current status, challenges, and future. European Heart Journal. 2014;35(12):765–76.
11. Zhang Y, Bourantas CV, Farooq V, Muramatsu T, Diletti R, Onuma Y, et al. Bioresorbable scaffolds in the treatment of coronary artery disease. Medical Devices (Auckland, NZ). 2013;6:37–48
12. Onuma Y, Serruys PW. Bioresorbable scaffold: The advent of a new era in percutaneous coronary and peripheral revascularization? Circulation. 2011;123(7):779–97.
13. Verheye S, Ormiston JA, Stewart J, Webster M, Sanidas E, Costa R, et al. A next-generation bioresorbable coronary scaffold system: From bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. JACC Cardiovascular Interventions. 2014;7(1):89–99
14. Nikolsky E, Mehran R, Dangas G, Fahy M, Na Y, Pocock SJ, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. European Heart Journal. 2007;28(16):1936–45
15. Kitabata H, Waksman R, Warnack B. Bioresorbable metal scaffold for cardiovascular application: current knowledge and future perspectives. Cardiovasc Revasc Med 2014;15:109-16
16. Diletti R, Serruys PW, Farooq V, et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J 2012;164:654-63
17. Kereiakes DJ, Ellis SG, Popma JJ, et al. Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: design of and rationale for the ABSORB III randomized trial. Am Heart J 2015;170:641-51
18. Biscaglia S, Ugo F, Ielasi A, et al. Bioresorbable Scaffold vs. Second Generation Drug Eluting Stent in Long Coronary Lesions requiring Overlap: A Propensity-Matched Comparison (the UNDERDOGS study). Int J Cardiol 2016;208:40-5
19. Sabaté M, Windecker S, Iñiguez A, et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J. 2016;37(3):229-40
20. Kimura T, Kozuma K, Tanabe K, et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015;36(47):3332-42
21. Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3-year, randomized, controlled, single-blind, multicenter trial. Lancet. 2016; Epub ahead of print.
22. Ellis SG, Kereiakes DJ, Metzger C, et al., on behalf of the ABSORB III Investigators. The 2-year Clinical Outcomes of the ABSORB III Trial:. Presented by Dr. Stephen Ellis at the American College of Cardiology Annual Scientific Session (ACC 2017), Washington, DC, March 18, 2017

Toplam 22 adet kaynakça vardır.

Ayrıntılar

Yazarlar	Mehmet Bülent Vatan Bu kişi benim Mustafa Tarık Ağaç Bu kişi benim Ersan Tatlı Bu kişi benim Muhammed Necati Murat Aksoy Bu kişi benim
Gönderilme Tarihi	22 Haziran 2017
Kabul Tarihi	6 Haziran 2017
Yayımlanma Tarihi	22 Haziran 2017
IZ	https://izlik.org/JA52AG93YS
Yayımlandığı Sayı	Yıl 2017 Cilt: 3 Sayı: 2

Kaynak Göster

APA	Vatan, M. B., Ağaç, M. T., Tatlı, E., & Aksoy, M. N. M. (2017). BİYOERİYEBİLEN STENTLER. Journal of Human Rhythm, 3(2), 92-97. https://izlik.org/JA52AG93YS
AMA	1.Vatan MB, Ağaç MT, Tatlı E, Aksoy MNM. BİYOERİYEBİLEN STENTLER. Journal of Human Rhythm. 2017;3(2):92-97. https://izlik.org/JA52AG93YS
Chicago	Vatan, Mehmet Bülent, Mustafa Tarık Ağaç, Ersan Tatlı, ve Muhammed Necati Murat Aksoy. 2017. “BİYOERİYEBİLEN STENTLER”. Journal of Human Rhythm 3 (2): 92-97. https://izlik.org/JA52AG93YS.
EndNote	Vatan MB, Ağaç MT, Tatlı E, Aksoy MNM (01 Haziran 2017) BİYOERİYEBİLEN STENTLER. Journal of Human Rhythm 3 2 92–97.
IEEE	[1]M. B. Vatan, M. T. Ağaç, E. Tatlı, ve M. N. M. Aksoy, “BİYOERİYEBİLEN STENTLER”, Journal of Human Rhythm, c. 3, sy 2, ss. 92–97, Haz. 2017, [çevrimiçi]. Erişim adresi: https://izlik.org/JA52AG93YS
ISNAD	Vatan, Mehmet Bülent - Ağaç, Mustafa Tarık - Tatlı, Ersan - Aksoy, Muhammed Necati Murat. “BİYOERİYEBİLEN STENTLER”. Journal of Human Rhythm 3/2 (01 Haziran 2017): 92-97. https://izlik.org/JA52AG93YS.
JAMA	1.Vatan MB, Ağaç MT, Tatlı E, Aksoy MNM. BİYOERİYEBİLEN STENTLER. Journal of Human Rhythm. 2017;3:92–97.
MLA	Vatan, Mehmet Bülent, vd. “BİYOERİYEBİLEN STENTLER”. Journal of Human Rhythm, c. 3, sy 2, Haziran 2017, ss. 92-97, https://izlik.org/JA52AG93YS.
Vancouver	1.Mehmet Bülent Vatan, Mustafa Tarık Ağaç, Ersan Tatlı, Muhammed Necati Murat Aksoy. BİYOERİYEBİLEN STENTLER. Journal of Human Rhythm [Internet]. 01 Haziran 2017;3(2):92-7. Erişim adresi: https://izlik.org/JA52AG93YS

Makale Dosyaları

Tam Metin